CTLA4 and non-small cell lung carcinoma: Several clinical trials with these agents have shown their benefit in key indications, including a 42% decrease in the relative risk of disease progression compared to the anti-CTLA-4 ipilimumab in melanoma patients and a 51% lower probability of death compared to placebo in non-small cell lung cancer (NSCLC) patients (16, 17).